Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
复制标题
DOI：
10.1016/j.molmed.2014.10.009
复制
发表时间：
2015-01
影响因子：
13.6
通讯作者：
Zang X
中科院分区：
文献类型：
--
作者：
Ohaegbulam KC;Assal A;Lazar-Molnar E;Yao Y;Zang X
PD-1受体和配体PD-L1和PD-L2，CD 28和B7家族的成员，在T细胞共抑制和耗竭中起关键作用。PD-L1和PD-1分别在肿瘤细胞和肿瘤浸润淋巴细胞上的过表达与某些人类癌症的不良疾病结局相关。已经开发了阻断PD-1/PD-L1通路的单克隆抗体（mAb），用于通过增强T细胞功能进行癌症免疫治疗。针对PD-1和PD-L1的mAb的临床试验显示了令人印象深刻的患者应答率，特别是对于黑色素瘤、非小细胞肺癌、肾细胞癌和膀胱癌。需要进一步的研究来剖析可变应答率的机制，鉴定临床应答的生物标志物，开发小分子抑制剂，以及与其他疗法联合收割机组合。
The PD-1 receptor and ligands PD-L1 and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer, renal cell carcinoma, and bladder cancer. Further studies are needed to dissect mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small molecule inhibitors, and to combine with other therapies.
登录
查看更多内容
影响因子：
6.5
作者：
Chapon, Maxime;Randriamampita, Clotilde;Bercovici, Nadege
通讯作者：
Bercovici, Nadege
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
11.5
作者：
Berger, Raanan;Rotem-Yehudar, Rinat;Nagler, Arnon
通讯作者：
Nagler, Arnon
影响因子：
32.4
作者：
Butte, Manish J.;Keir, Mary E.;Freeman, Gordon J.
通讯作者：
Freeman, Gordon J.
影响因子：
11.2
作者：
Ding ZC;Lu X;Yu M;Lemos H;Huang L;Chandler P;Liu K;Walters M;Krasinski A;Mack M;Blazar BR;Mellor AL;Munn DH;Zhou G
通讯作者：
Zhou G